General Information of Drug Combination (ID: DC3V3N3)

Drug Combination Name
Diethylcarbamazine Eflornithine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Diethylcarbamazine   DM1TJ8F Eflornithine   DMJOQM3
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 15.74
Bliss Independence Score: 15.74
Loewe Additivity Score: 30.13
LHighest Single Agent (HSA) Score: 30.14

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Diethylcarbamazine
Disease Entry ICD 11 Status REF
Elephantiasis N.A. Approved [2]
Loiasis N.A. Approved [2]
Lymphatic filariasis 1F66.3 Approved [3]
Onchocerciasis 1F6A Approved [2]
Diethylcarbamazine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Arachidonate 5-lipoxygenase (5-LOX) TT2J34L LOX5_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------
Diethylcarbamazine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Activity [8]
------------------------------------------------------------------------------------
Indication(s) of Eflornithine
Disease Entry ICD 11 Status REF
African trypanosomiasis 1F51 Approved [4]
Trypanosomiasis 1D51-1F53 Phase 2 [5]
Colon cancer 2B90.Z Investigative [6]
Familial adenomatous polyposis 2B90.Y Investigative [6]
Eflornithine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ornithine decarboxylase (ODC1) TTUMGNO DCOR_HUMAN Inhibitor [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Diethylcarbamazine FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5176).
5 ClinicalTrials.gov (NCT01636128) Urinary Biomarker Study With Sulindac and Difluoromethylornithine. U.S. National Institutes of Health.
6 Eflornithine FDA Label
7 Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
8 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
9 Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43.